Median time to response was rapid (1.9 months), based on 2 open-label, single-arm trials that did not include comparisons to other treatments (first assessment was performed at 8 weeks; range: 1.7-7.6 months)
47.2% ORR (51 of 108 patients;
95% Cl, 37.5%, 57.1%)
43.5% PR (47 of 108 patients)†;
3.7% CR (4 of 108 patients)‡
61% of responders (31 of 51) reached
a DoR of ≥6 months1,2
Median DoR was not reached
(range: 1-15.2+ months)1-3
80% of responses (41 of 51) were ongoing at last response assessment2
Each bar in the figure represents best percent change from baseline in the sum of target lesions based on RECIST 1.1 (bars without a dot) or the sum of products of externally visible target lesions based on WHO Criteria (bars with a dot) during the study period in the 87 patients with at least 1 evaluable tumor assessment. Lesion measurements after progression are excluded. Increases in the sum of target lesions greater than 100% are reported as 100%.